{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000112","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-08-03T12:11:28+00:00","discovered_at":"2026-08-03T12:15:00.355162+00:00","generated_at":"2026-08-03T12:15:04.909700+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Autolus raises FY2026 AUCATZYL revenue guidance to $140-150M, secures up to $250M credit facility","bullets":["Preliminary Q2 2026 AUCATZYL net product revenue ~$45M, up ~70% QoQ and >100% YoY.","FY2026 net product revenue guidance raised to $140-150M from $120-135M.","Gross margin improved to ~35% in H1 2026 from negative ~20% in H2 2025.","Entered five-year interest-only credit facility with Perceptive Advisors for up to $250M; initial $75M funded.","Cash runway extended into Q2 2028; additional $150M available upon revenue milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000112","json":"https://secwatch.observer/filing/0001730463-26-000112.json","markdown":"https://secwatch.observer/filing/0001730463-26-000112.md","text":"https://secwatch.observer/filing/0001730463-26-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/0001730463-26-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/autl-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T12:15:04.909700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}